CEO Natalie Holles describes how learnings from a setback from the company's first asset have resulted in a new program.

Jim Porter describes the chemistry that has led to early stage success against ALK and ROS1.

Mark Valleca describes Black Diamond's 'MasterKey' approach to precision oncology that's aimed at solving many mutations at once.

Scientific founder, president & CEO J. Jean Cui describes her scientific approach of working to solve resistance mutations.

Fred Aslan describes how Artiva is harnessing the ability of NK cells to act as a modulator of antibody dependent cellular cytotoxicity.

He describes how Fog is leveraging the way α-helices mediate interactions with other proteins to solve the undruggable problem.

Andy Schwab describes founding 5AM in 2002 and discusses portfolio companies Radionetics, Latigo, TMRW, and Skye Bioscience.

Joseph Panetta introduces the conference and we discuss the state of biotech in California's numerous biotech hubs.

He discusses some of the key theme of the conference including obesity, IgG, ATTR cardiomyopathy, and more.

He describes what made him excited about the company, and why he views diabetic retinopathy as potentially a bigger opportunity than wet AMD

Ying Huang talks about Friday's CHMP positive opinion and the upcoming FDA advisory committee meeting, and highlight's Legend's pipeline.

Craig Tooman describes Silence's two lead programs targeting Lp(a) and polycythemia vera, as well as the company's broader platform.

On the heels of a historic recent approval for the class, Lynn Seely describes the science behind TIL therapies.

Kevin Parker describes how Cartography has been building an antigen map over previous years.

Paul Matteis gives his take on biotech's start to the year and comments on Alnylam, Biogen, Vertex, KalVista, Denali, Acadia, and more.

Raphael Townshend describes how the company has used AI and large language models to understand the structure and function of RNA.

Cognito CEO Brent Vaughan introduces the company's device and walks us through the randomized P2 study.

Daphne Koller describes the platform insitro has been building since it was founded in 2018.

The event leveraged the substantial biotech industry and investor presence that exists in the Greater Bay Area around Stanford.